Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

More states are opening the door to psychedelics, with seven states already passing laws over the last several months to allow research or decriminalize its use and another 11 considering similar measures.

Why it matters: There's a growing body of research suggesting psychedelic compounds with psychotherapy can be effective for anxiety, depression, post-traumatic stress disorder and substance use disorder where other therapies have failed.

  • Amid a national epidemic of opioid abuse and suicides, state legislatures see a greater need to explore new therapeutics.

What's happening: In November, Oregon became the first to legalize psychedelics in licensed, supervised facilities and decrimalize them elsewhere.

In the months following, several states have passed bills to consider allowing the study of the medical risks and benefits of psilocybin, the active ingredient in psychedelic mushrooms.

  • Texas, Gov. Greg Abbott (R) allowed a bill authorizing the study of psilocybin to become law without his signature on June 18.
  • Connecticut Gov. Ned Lamont signed a bill of health initiatives on June 7 that called for the state's department of mental health and addiction services to report findings by Jan. 1, 2022.
  • In New York, a bill was introduced on June 1 that would require the state to establish an institute to investigate the medical potential of substances including “ibogaine, LSD, psilocybin and certain other psychedelic drugs.”
  • California's legislature is considering a bill that, if ultimately passed, would make California the second state next to Oregon to decriminalize psilocybin.

The big picture: MDMA and psilocybin have been granted breakthrough therapy status by the Food and Drug Administration, signaling a shift in the potential for incorporating psychedelics into the existing health care infrastructure.

  • Psychedelic drug developer ATAI Life Sciences, backed by Peter Thiel, went public last month. It's one of three such psychedelics companies including MindMed and Compass Pathways that have both gone public in the last year.
  • More state, federal and even company-sponsored research is beneficial to corroborate early, smaller studies that "show great promise," George Goldsmith, CEO of Compass Pathways, a psychedelic therapy developer that finished its psilocybin therapy IIb clinical trial this week.

The other side: There's a debate between policy advocates on whether state-accelerated research alone could be too slow-moving. And in plenty of other states, the political will isn't there to pass this kind of measure.

  • In February, an Iowa lawmaker filed a bill that would allow seriously ill people to use psilocybin mushrooms, MDMA, LSD, DMT or peyote as alternative treatments after they’ve exhausted traditional legal medicines. It died in committee.

Go deeper

Updated 37 mins ago - Politics & Policy

Bipartisan police reform negotiations end without deal

Rep. Karen Bass (D-Calif.) with Sens. Tim Scott (R-S.C.) and Cory Booker (D-N.J.) in the Capitol in May 2021. Photo: Drew Angerer/Getty Images

Bipartisan talks on reforming police tactics and accountability, prompted by George Floyd's murder in May 2020, have ended without a compromise, Sen. Cory Booker (D-N.J.), a key negotiator, said Wednesday.

Why it matters: Lawmakers, led by Rep. Karen Bass (D-Calif.) and Sens. Tim Scott (R-S.C.) and Booker, had been working toward a bipartisan deal for months but things fell apart due to disagreements on qualified immunity and other issues.

Federal Reserve scales back expectations for economic recovery as Delta variant weighs

Fed chair Jerome Powell during a congressional hearing last year. (Photo: Stefani Reynolds/Bloomberg via Getty Images)

The Fed downgraded near-term expectations for the economy and the labor market, alongside hotter-than-expected inflation, in new estimates out on Wednesday.

Why it matters: It's the first time those closely-watched estimates reflect impact from the delta variant that's already rattled the labor market. Still, Fed chairman Jerome Powell said enough progress has been made to begin to pull back emergency-era measures that have supported the economy.

Biden speaks with Macron for first time since diplomatic crisis

President Biden and French President Emmanuel Macron have a conversation ahead of the NATO summit in Brussels, on June 14, 2021. Photo: Dursun Aydemir/Anadolu Agency via Getty Images

President Biden on Wednesday spoke with French President Emmanuel Macron for the first time since a diplomatic row erupted over a scrapped submarine order, per the White House.

Driving the news: Macron said that the French ambassador will return to Washington next week and will resume working with senior U.S. officials.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!